Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 17 July 2024
Suspected Cancer: recognition and referral (update)Status:In developmentProgramme:NICE guidelineExpected publication date: 27 March 2026
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 29 July 2026
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 29 October 2026
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tiragolumab with atezolizumab and bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [TSID12238]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC